← All trials
NCT05314764
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2022
- Primary completion
- May 31, 2023
- Completion date
- Jun 30, 2023
- First posted
- Apr 6, 2022
- Last posted
- Dec 23, 2022
- Enrollment
- 12
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ConnecticutLead sponsor
- ShionogiCollaborator
- University of PittsburghCollaborator
- Indiana UniversityCollaborator
- University of ConnecticutOverall official - principal investigator
- University of ConnecticutReponsible party - principal investigator
- University of Texas, GalvestonCollaborator
- Keystone Bioanalytical, Inc.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.